Children undergoing cardiac surgery are at risk of developing acute kidney injury (AKI). Preventing cardiac surgery-associated AKI (CS-AKI) is important as it is associated with increased early-and long-term mortality and morbidity. Targeting modifiable risk factors (eg, avoiding poor renal perfusion, nephrotoxic drugs, and fluid overload) reduces the risk of CS-AKI. There is currently no strong evidence for the routine use of pharmacological approaches (eg, aminophylline, dexmedetomidine, fenoldopam, and steroids) to prevent CS-AKI. There is robust evidence to support the role of early peritoneal dialysis as a nonpharmacologic approach to prevent CS-AKI.
Introduction
Acute kidney injury (AKI) after pediatric cardiac surgery is increasingly being diagnosed. Older studies performed in the 1970s to 1980s focused on what we now consider as later stages of AKI and reported incidence of AKI to be 5% to 8% of children undergoing cardiac surgery.
1,2 Using current definitions to allow for an earlier identification of AKI, pediatric cardiac surgery-associated AKI (CS-AKI) is now recognized as a common phenomenon with an estimated incidence of 32% to 52%, [3] [4] [5] with an associated mortality of 5.2% to 12%. Furthermore, CS-AKI is associated with increased need for inotropic support, infections, and prolonged duration of mechanical ventilation, intensive care unit (ICU), and hospital stays. [3] [4] [5] [6] The increase in mortality and morbidity in children with CS-AKI is attributed to numerous factors: fluid overload effects on the lungs resulting in prolonged mechanical ventilation, increased risk of nosocomial infections due to the increased need for mechanical ventilation and renal replacement therapy (RRT), and interactions between the heart and the kidneys via cytokines and chemokines (ie, cardiorenal syndrome). 3, 7 In children and adults undergoing cardiac surgery with cardiopulmonary bypass (CPB), even a small increase in serum creatinine has been demonstrated to be associated with adverse outcomes. 8, 9 The long-term renal prognosis (eg, chronic kidney disease, hypertension) in children with CS-AKI is increasingly important with improving survival and with increasing complexity of cardiac surgeries. OR children OR infants OR neonates." We also performed a manual search of references from original studies and review articles to identify any additional relevant studies. In areas where there is paucity of pediatric data, we included evidence from adult patients so as to enable the reader to get a better understanding on the current state of evidence in that particular area.
Pathogenesis and Risk Factors for CS-AKI
Cardiopulmonary bypass is central to the pathogenesis of CS-AKI ( Figure 1 ). The low-pressure nonpulsatile linear flow during CPB leads to elevation of peripheral vascular resistance and poor microcirculation that results in ischemia-perfusion injury and tissue edema. 13 In addition, increased cortical perfusion paradoxically precipitates corticomedullary ischemia due to increased medullary oxygen consumption.
14 Furthermore, low cardiac output states lead to sympathetic nervous system activation, resulting in the endogenous release of catecholamines and induction of the renin-angiotensin-aldosterone cascade, further impairing renal oxygenation. 15, 16 Ischemia-reperfusion injury and exposure of blood to the CPB circuit lead to systemic inflammation, subsequently inducing reactive oxygen species (ROS) production and upregulation of pro-inflammatory transcription factors. Cytokines and chemokines recruit neutrophils, macrophages, and lymphocytes into the renal parenchyma, resulting in fibrosis. 17 Elevated postoperative plasma concentrations of inflammatory cytokines are associated with AKI and increased mortality. 18 Furthermore, the CPB circuit causes hemolysis, releasing free hemoglobin (Hb) and iron. Free Hb depletes circulating haptoglobin and precipitates with Tamm-Horsfall protein, leading to renal tubular congestion and injury. 19 Plasma oxyhemoglobin consumes nitric oxide, inducing renal arteriole vasoconstriction and subsequently impairing kidney perfusion.
Circulating labile iron increases ROS production via the Fenton and Haber Weis reactions, further aggravating oxidative stress and AKI. 17 In addition to the role of CPB, there are numerous modifiable risk factors that contribute to the development of pediatric CS-AKI (Table 1) . One important risk factor that has been studied extensively is fluid overload. Cumulative fluid volume >500 mL/kg administered through postoperative day (POD) 4 had 100% sensitivity and 91% specificity for the "failure" stage of the pediatric-modified Risk, Injury, Failure, Loss, and EndStage Kidney Disease (pRIFLE) classification (area under the curve:0.96; 95% confidence interval [CI] 0.92-1.00; P ¼ .002). 23 Children after cardiac surgery are often exposed to nephrotoxic medications. To address this issue, Goldstein et al recently published encouraging results utilizing a systematic electronic health record to monitor serum creatinine (SCr) of patients receiving intravenous aminoglycoside for !3 days or !3 nephrotoxic drugs simultaneously. 33 This surveillance process was associated with a 42% reduction in AKI intensity (AKI days per 100 exposure days). Another common exposure in this patient population is angiography. Children undergoing angiography before cardiac surgery should be exposed to the lowest possible dose of contrast media dose and iodine.
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Patients with postcardiac surgery pRIFLE stage "failure" received a significantly larger dose of iodine contrast media, when they underwent angiography prior to their cardiac surgery, compared to the other patients without AKI (4.6 + 2.6 vs 2.8 + 2.2 g/kg; P < .001). After adjusting for age and the presence of a postoperative low cardiac output syndrome, iodine dose on angiography was associated with postoperative AKI, with a relative risk increase in AKI of 16% per each incremental iodine dose of 1 g/kg.
Various Metrics and Definitions for AKI
Defining AKI is an important step in determining the effectiveness of preventive strategies. By identifying subclinical AKI (ie, latent AKI or acute kidney stress), one may prevent progression to SCr-defined, overt AKI. 34 Serum creatinine reflects a functional decrease in glomerular filtration rate (GFR) and lags behind structural damage in early AKI, rising 24 to 72 hours after injury has occurred and when >50% of kidney function is lost. As a result, recognition of AKI and institution of appropriate interventions may be delayed. 35 Despite its current limitations, SCr is still used most commonly in AKI definitions: pRIFLE, 36 Kidney Disease: Improving Global Outcomes (KDIGO), 37 and Acute Kidney Injury Network (AKIN) 38 scores ( Table 2) . Among these definitions, pRIFLE appears to be the most sensitive, whereas AKIN is more specific and detects high-risk patients or clinically significant AKI.
39,40 Until a new practical gold standard is validated, SCr remains an important determinant in the assessment of perioperative renal function and in the prediction of adverse outcome in cardiac surgery. 41 Although urine output (UOP) is used as a criterion in all the abovementioned scores, classification of AKI in children is not altered significantly when UOP is included in addition to SCr, indicating that UOP is not a robust parameter in defining AKI. 36 Alternative methods of identifying CS-AKI, such as fluid overload, have been studied. It has been shown that pediatric cardiac surgical patients with fluid overload have a higher rate of postoperative AKI. 23, 24, 42 Failure to correct SCr for fluid balance underestimates the prevalence of AKI. Correction of SCr for fluid balance resulted in shifts between AKI stages. 43, 44 Because of the limitations of SCr and UOP as markers of AKI, alternative biomarkers have been investigated (Table 3) . These can be characterized into markers of glomerular or tubular injury, inflammation or cell cycle arrest, with potential of multiple biomarker profiles being more predictive of AKI. 65, 66 In addition, several urinary biomarkers exhibit a temporal relationship after pediatric CPB. During early stages of ischemic insult, elevations in neutrophil gelatinase-associated lipocalin may be detected. When prolonged ischemia is followed by reperfusion, tubules undergo cell death, and injured endothelial and epithelial cells amplify the inflammatory cascade, leading to the rise of liver-type fatty acid-binding protein and interleukin (IL)-18. Later, when cell injury and regeneration occur simultaneously, detection of kidney injury molecule 1 may be most effective. 66 This temporal relationship may potentially influence the choice of biomarker being utilized in clinical practice. However, these biomarkers are still used to complement pRIFLE, KDIGO, and AKIN, rather than being utilized individually to define or stage AKI. 57 Cystatin C (CysC) is a cationic nonglycosylated lowmolecular-weight protein that inhibits cysteine proteases and is produced in all nucleated cells. Cystatin C is freely filtered at the glomerulus, then reabsorbed, and metabolized in the tubules. Cystatin C is thought to better reflect GFR than SCr because of its shorter half-life of approximately 2 hours and is less affected by volume status, protein intake, muscle mass, age, and gender. 52, 67, 68 In children, serum CysC has been demonstrated to be able to predict subsequent development of CS-AKI before changes in SCr levels. 53, 54 However, CysC levels can be affected by multiple factors including corticosteroid use, thyroid function, malignancies, and inflammation, making interpretation of the levels challenging in certain clinical scenarios. 55, 56 Elevation of IL-6, a pro-inflammatory cytokine, during the pre-and postoperative (2 and 6 hours after surgery) periods has been demonstrated to be predictive of pediatric CS-AKI. [62] [63] [64] 69 Interleukin 6is upregulated and released from renal tubular epithelial cells in response to injury and plays a fundamental role in the pathophysiology of AKI, 70 but its production increases in many inflammatory and immunologic processes, 71 as well as in states of congestive heart failure, cardiac ischemia, and congenital heart disease. 72, 73 Renal near-infrared spectroscopy (NIRS) has been proposed as a noninvasive, continuous method of evaluating real-time regional oximetry. However, the use of NIRS is limited by potential confounders such as patient size, kidney depth, amount of subcutaneous fat, and use of certain medications. 74 There has been inconsistency in current studies on the association between renal NIRS and AKI.
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Pharmacological Preventive Strategies
Because of the potential impact on short-and long-term morbidities, there is substantial interest in performing studies on the effectiveness of pharmacological (Table 4) and nonpharmacological strategies in preventing pediatric CS-AKI.
Aminophylline
In the kidney, adenosine is the main messenger molecule for tubuloglomerular feedback. In the presence of angiotensin II, adenosine constricts the afferent arteriole and decreases glomerular blood flow. Adenosine blockade (selective or nonselective) has been demonstrated to attenuate AKI secondary vasoconstriction induced by hypoxic-ischemic injury. 91 Nonselective adenosine receptor antagonists (eg, aminophylline and theophylline) have been demonstrated to be effective in preventing AKI in children in several pediatric settings: pediatric cardiovascular ICU, 92 calcineurin inhibitor nephrotoxicity, 93 and asphyxiated neonates.
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Dexmedetomidine
The postulated mechanisms of dexmedetomidine's renoprotective properties include anti-inflammatory, sympatholytic, and cytoprotective effects. 94 The reduced sympathetic drive induced by dexmedetomidine may modulate vasoreactivity and improve renal blood flow through downregulation of endothelin 1. Activation of a2-adrenoceptors by dexmedetomidine has been shown to inhibit renin release and increase glomerular filtration and secretion of sodium and water by opposing the activity of vasopressin at the collecting ducts. 94 Dexmedetomidine reduces the incidence and severity of contrast-induced nephropathy in children undergoing cardiac angiography. 95 In adults, the use of dexmedetomidine was associated with a lower incidence of CS-AKI. 96, 97 A retrospective study of 204 children post-CPB demonstrated that patients receiving dexmedetomidine had lower risk of AKI (adjusted odds ratio [OR] 0.43; 95% CI: 0.27-0.98; P ¼ .048). 81 
Fenoldopam
Fenoldopam, a selective dopamine 1 receptor agonist, produces a dose-dependent increase in renal plasma flow with a decrease in renal vascular resistance and maintenance of GFR, increases blood flow to the renal cortex and medulla, and inhibits tubular reabsorption of sodium. 98 The effect of fenoldopam on reducing CS-AKI in the adults has been controversial. 99, 100 A retrospective study involving 25 neonates after cardiac surgery showed increased UOP when fenoldopam was started after diuretics. 82 A higher dose appears to be more effective in reducing pediatric CS-AKI. 84 
Steroids
Although anti-inflammatory effects of steroids after CPB have been demonstrated, its use to prevent CS-AKI remains unclear. 101 In a randomized controlled trial (RCT), the incidence of increase in SCr !0.2mg/dL was lower in children who received dexamethasone before cardiac surgery, as compared to children who did not. 85 However, a subsequent RCT did not show benefits of preoperative methylprednisolone. 86 More recently, 2 RCTs compared postoperative hydrocortisone versus placebo-one demonstrated less need for peritoneal dialysis 87 and the other showed higher UOP and more negative fluid balance. 
Acetaminophen
It has been previously demonstrated that patients who develop CS-AKI have greater hemoglobinemia and lipid peroxidation compared to controls. 19 In animal models, acetaminophen inhibits hemeprotein-mediated lipid peroxidation and protects kidney function. 102 Intravenous acetaminophen reduced plasma concentrations of isofurans, biomarkers of oxidative stress, in adults and children undergoing cardiac surgery but did not affect AKI or urinary markers. 90, 103 Overall, there is no strong evidence to support the use of any of these drugs to prevent CS-AKI in children. More research is needed in children to determine the optimal dose, timing, and duration of these strategies.
Nonpharmacological Preventive Strategies
Among the nonpharmacological strategies investigated to decrease CS-AKI, early postoperative peritoneal dialysis (PD) holds the most promise. Other strategies include remote ischemic preconditioning (RIPC), particle-retentive in-line filtration, and CPB modifications.
Early PD
Preventing fluid overload may prevent pediatric CS-AKI (Figure 1) . By reducing the degree of fluid overload, early RRT initiation may improve prognosis in critically ill children. 104, 105 Although this strategy has shown to improve the overall outcome, its role in preventing CS-AKI is still being investigated. 106, 107 Children at risk of CS-AKI should be considered for early PD. Early PD after pediatric cardiac surgery has been demonstrated to be safe and effective. Two observational studies 108, 109 (total N ¼ 206) demonstrated that UOP was significantly higher post-PD, compared to those who did not have PD. Furthermore, in a prospective cohort study, prophylactic PD resulted in greater negative net fluid balance with higher UOP at 24 and 48 hours. 110 In addition, early PD has the potential benefit of removal of inflammatory mediators such as IL-6, IL-8, and IL-10 but the resultant clinical impact remains to be determined.
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Remote Ischemic Preconditioning
Remote ischemic preconditioning induces brief transient episodes of ischemia at a site remote from vital organs (eg, the arm or leg) before organs are exposed to prolonged periods of ischemia and reperfusion. Remote ischemic preconditioning is hypothesized to attenuate renal damage by inducing the release of signaling molecules that activate Toll-like receptors in the proximal tubule epithelia, conditioning the epithelium to tolerate a subsequent inflammatory or ischemic stress. 113 Four RCTs performed on children undergoing cardiac surgery comparing RIPC versus control group showed no significant difference in renal biomarkers, [114] [115] [116] incidence of AKI, 114 postoperative SCr, 115, 117 and UOP. 116 Overall, studies do not support RIPC in preventing pediatric CS-AKI.
Particle-Retentive In-Line Filtration
Particles arising from infusion therapy may aggravate the inflammatory response from CPB, predisposing to thrombosis, impaired microcirculation, and immune response. Sources of particles include components of infusion systems, incomplete reconstitution of solutions, or drug incompatibility reactions. In-line filters incorporated into infusion lines retain particles and almost completely prevent particle infusion. In critically ill children, in-line filtration was associated with reduced AKI and other organ dysfunction. 119 In a subsequent larger study of 305 pediatric cardiac intensive care patients, who were randomized to either filter or control group, patients who received in-line filter had lower incidence of AKI (risk difference: À10%; 95% CI: À17% to À3%).
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Specific Strategies of CPB Support
Numerous studies have examined specific strategies to reduce the impact of CPB on the development of AKI. A retrospective review of 102 children postcardiac surgery demonstrated that novel bypass strategies to preserve renal function (maintenance of higher hematocrit [32% instead of 25%] and high flow rates on CPB despite systemic hypothermia [>175 mL/kg/min for patients weighing >2.5 kg, 200 mL/kg/min for patients 2-2.5 kg and 225 mL/kg/min for patients <2.0 kg, instead of 150 mL/kg/min], targeting nasal temperature of about 13 C [instead of 18 C], and avoidance of albumin [including albumin-free priming of CPB circuit]) and milrinone in the perioperative period resulted in only 11 (11%) patients having CS-AKI. 121 Another strategy to prevent pediatric CS-AKI is to reduce priming volume, dilution of autologous blood, and contact with foreign surfaces, thus reducing systemic inflammatory responses. In a retrospective study in adults post-CPB, Ranucci et al demonstrated that patients who received low priming volume had lower risks of AKI. 122 Till date, there are no studies to investigate whether low priming volume reduces pediatric CS-AKI.
Hemodilution during CPB contributes to AKI postcardiac surgery by impairment of oxygen delivery to the hypoxic kidney medulla. However, hemoconcentration may increase the blood viscosity and impair renal microvascular circulation. In serum IL-6, and 6 hours postoperative urine IL-658 predicted pediatric CS-AKI Abbreviations: CPB, cardiopulmonary bypass; CS-AKI, cardiac surgery-associated acute kidney injury; CysC, cystatin C; FDA, Food and Drug Administration; HLHS, hypoplastic left heart syndrome; IGFBP7, insulin-like growth factor-binding protein 7; IL, interleukin; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of metalloproteinases. a Other promising but less studied biomarkers of pediatric CS-AKI include apolipoprotein M, urinary albumin, homovanillic acid sulfate, fibroblast growth factor 23, syndecan 1, and semaphoring 3A. The effect of other modifications in CPB techniques, such as utilization of pulsatile CPB, 127 ultrafiltration, 128 and hemofiltration 129 during CPB on CS-AKI have only been predominantly described in the adult cardiac population. However, these have not been widely studied in children.
Conclusion
Acute kidney injury in children after cardiac surgery is an independent factor that impacts on short-and long-term morbidity and mortality. A better understanding of its pathogenesis will help in finding more effective renopreventive strategies. More RCTs on pharmacological approaches to prevent AKI are needed. More studies are required in studying the impact of early intraoperative RRT and particle-retentive in-line filtration in preventing CS-AKI. With improving mortality rates after congenital heart surgery, emphasis should be given to prevent complications such as development of AKI so as to minimize cost and morbidities in children undergoing cardiac surgery.
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